The vast majority of money spent on today’s cancer research and care works to marginally benefit patients. “One key factor is the shift over the past few decades from predominantly publicly funded clinical trials designed to answer questions important to patients, to industry funded trials designed to achieve regulatory approval or commercial advantage…predominantly focused on new cancer medicines at the expense of investigating new approaches to surgery, radiotherapy, palliative care, and prevention. Surgery and radiotherapy cure many more patients than cancer medicines, yet receive much less funding for research and delivery of care.” Thus the creation of the Common Sense Oncology (CSO) initiative to generate, interpret and communicate patient-centered oncologic research that matters more to patients than the commercial bottom line. | Booth, Lancet Oncol 2023
